Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study

American Journal of Epidemiology

Volumn 172, Issue 10, 2010, Pages 1181-1189

  Braem, M G M ^a   Onland Moret, N C ^a   Van Den Brandt, P A ^b   Goldbohm, R A ^c   Peeters, P H M ^a   Kruitwagen, R F P M ^b   Schouten, L J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Hormones; infertility; ovarian neoplasms; prospective studies; reproductive history

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT;

CANCER; COHORT ANALYSIS; CONTRACEPTIVE USE; HEALTH RISK; HORMONE; INFERTILITY; PREGNANCY; QUESTIONNAIRE SURVEY; WOMENS HEALTH;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BIRTH; CANCER INVASION; CANCER RISK; COHORT ANALYSIS; DIET; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIFESPAN; MAJOR CLINICAL STUDY; MARRIAGE; MENARCHE; MENOPAUSE; NETHERLANDS; NULLIPARA; ORAL CONTRACEPTION; OVARY CANCER; PARITY; POSTMENOPAUSE; PREGNANCY; QUESTIONNAIRE; REPRODUCTION; SELF CONCEPT;

AGE FACTORS; AGED; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; INFERTILITY, FEMALE; MIDDLE AGED; NETHERLANDS; OVARIAN NEOPLASMS; PARITY; POSTMENOPAUSE; PREGNANCY; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; RISK FACTORS; TIME FACTORS;

NETHERLANDS;

EID: 78149299775     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq264     Document Type: Article

References (75)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18(3):581-592.
2. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932): 1250-1254.
3. Albrektsen G, Heuch I, Kvale G. Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control. 1996;7(4):421-427.
4. Chiaffarino F, Parazzini F, Decarli A, et al. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol. 2005;97(2):318-322.
5. Chiaffarino F, Parazzini F, Negri E, et al. Time since last birth and the risk of ovarian cancer. Gynecol Oncol. 2001;81(2): 233-236. (Pubitemid 32424167)
6. Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol. 2001;12(3): 337-341.
7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609): 303-314.
8. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 1995;5(4):310-314.
9. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45-53.
10. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer. 1997;71(6): 948-951.
11. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284-290.
12. Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2):237-243.
13. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol. 2001;11(8):568-574.
14. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and post-menopausal women. Am J Epidemiol. 2008;167(9): 1059-1069.
15. Moorman PG, Palmieri RT, Akushevich L, et al. Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 2009;170(5):598-606.
16. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7):585-597.
17. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5(11):933-935.
18. Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84(5):714-721.
19. Tung KH, Wilkens LR, Wu AH, et al. Effect of anovulation factors on pre-and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol. 2005;161(4):321-329.
20. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007; 166(8):894-901.
21. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184-1203. (Pubitemid 23026890)
22. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol. 2004;92(1):320-326. (Pubitemid 38147409)
23. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004; 82(2):405-414.
24. Hardiman P, Nieto JJ, MacLean AB. Infertility and ovarian cancer. Gynecol Oncol. 2000;76(1):1-2.
25. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 1997;67(6):1005-1012.
26. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155(3):217-224.
27. Rodriguez C, Tatham LM, Calle EE, et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control. 1998;9(6):645-651. (Pubitemid 29046138)
28. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160(11): 1070-1078.
29. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003;158(7): 629-638.
30. van den Brandt PA, Goldbohm RA, van't Veer P, et al. A large-scale prospective cohort study on diet and cancer in the Netherlands. J Clin Epidemiol. 1990;43(3):285-295.
31. van den Brandt PA, Schouten LJ, Goldbohm RA, et al. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol. 1990;19(3):553-558.
32. Goldbohm RA, van den Brandt PA, Dorant E. Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge data. Tijdschr Soc Ge-zondheidsz. 1994;72:80-84.
33. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2): 442-451.
34. Pelucchi C, Galeone C, Talamini R, et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol. 2007;196(1):83.e1-87.e1. (doi:10.1016/ j.ajog.2006.06.088).
35. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50(4):1064-1072.
36. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott-Raven 2008.
37. Kleinbaum DG. Survival Analysis. New York, NY: Springer; 1996.
38. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
39. Greenhall E, Vessey M. The prevalence of subfertility: a review of the current confusion and a report of two new studies. Fertil Steril. 1990;54(6):978-983.
40. Joffe M. Time to pregnancy: a measure of reproductive function in either sex. Asclepios Project. Occup Environ Med. 1997;54(5):289-295.
41. Joffe M, Paranjothy S, Fielder H, et al. Use of time to pregnancy in environmental epidemiology and surveillance. J Public Health (Oxf). 2008;30(2):178-185.
42. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 2002; 102(3):262-265.
43. Kumle M, Weiderpass E, Braaten T, et al. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer. 2004;90(7): 1386-1391.
44. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152(3): 233-241.
45. Fathalla MF. Incessant ovulation\-a factor in ovarian neo-plasia [letter]? Lancet. 1971;2(7716):163.
46. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:932371. (doi:10.1155/2010/ 932371).
47. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-443.
48. Levanon K, Crum C, Drapkin R. New insights into the path-ogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284-5293.
49. Piek JM, Kenemans P, Zweemer RP, et al. Ovarian carcino-genesis, an alternative theory [letter]. Gynecol Oncol. 2007; 107(2):355.
50. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104(2): 228-232.
51. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR 2007.
52. Jordan SJ, Siskind V, Green AC, et al. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2010; 21(1):109-116.
53. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control. 2007;18(5):517-523.
54. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90(23):1774-1786.
55. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14(1):98-107.
56. Rostgaard K, Wohlfahrt J, Andersen PK, et al. Does pregnancy induce the shedding of premalignant ovarian cells? Epidemiology. 2003;14(2):168-173.
57. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology. 1999;57(suppl 2): 45-48.
58. Chan CC, Ng EH, Ho PC. Ovarian changes after abdominal hysterectomy for benign conditions. J Soc Gynecol Investig. 2005;12(1):54-57.
59. Halmesmäki KH, Hurskainen RA, Cacciatore B, et al. Effect of hysterectomy or LNG-IUS on serum inhibin B levels and ovarian blood flow. Maturitas. 2007;57(3):279-285.
60. Xiangying H, Lili H, Yifu S. The effect of hysterectomy on ovarian blood supply and endocrine function. Climacteric. 2006;9(4):283-289.
61. Massuger L, Roelofsen T, Ham M, et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses. 2010;74(5):859-861.
62. Whiteman DC, Siskind V, Purdie DM, et al. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(1):42-46. (Pubitemid 36110156)
63. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer. 1991;49(1):57-60.
64. Schildkraut JM, Cooper GS, Halabi S, et al. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol. 2001;98(1):85-90.
65. Polychronopoulou A, Tzonou A, Hsieh CC, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer. 1993;55(3): 402-407.
66. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol. 2002;156(4):363-373. (Pubitemid 34858005)
67. Greggi S, Parazzini F, Paratore MP, et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol. 2000;79(1): 50-54.
68. Jordan SJ, Webb PM, Green AC. Height, age at menarche, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):2045-2048.
69. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95(6):370-374.
70. Beral V, Million Women Study Collaborators, Bull D, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703-1710. (Pubitemid 46755369)
71. Garg PP, Kerlikowske K, Subak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92(3):472-479.
72. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update. 2007;13(5): 453-463.
73. Mills PK, Riordan DG, Cress RD, et al. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev. 2005;29(2):124-132.
74. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol. 2008;108(3):641-651.
75. Goodman LS, Gillman A. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1985.